Rhythm is a biopharmaceutical company dedicated to changing how rare genetic disorders of obesity are diagnosed and treated.

Disorders of severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key pathway responsible for regulating weight, that lead to excessive or insatiable hunger or hyperphagia. Rhythm’s MC4R agonist, setmelanotide, is being evaluated in multiple late-stage clinical studies. The company is also leading efforts to improve patient identification and diagnosis through genetic testing and deepen the community’s understanding of the ongoing impact and burden of disease on patients and caregivers.

Meet the Rhythm leadership team and Board of Directors

David Meeker, MD


Chairman, President
and Chief Executive Officer

Jennifer Chien


Executive Vice President,
Head of North America

Simon Kelner


Chief Human Resources
Officer

Yann Mazabraud


Executive Vice President,
Head of International

Hunter Smith


Chief Financial
Officer

Murray Stewart, MD


Chief Medical
Officer

Satej Bhandarkar


Senior Vice-President, Program Management, Strategy and Corporate Development

Jim Flaherty


Senior Vice President
and General Counsel

Alastair Garfield


Vice President,
Head of Research

Joe Shulman


Senior Vice President,
Technical Operations

Irene Aquino


Vice President, Patient Engagement
Advocacy and Support

Brieana Buckley


Vice President,
Medical Affairs

Gregory Gordon


Vice President,
Clinical

Joanne E. Totosy de Zepetnek


Vice President,
Regulatory Affairs and Quality

Rhythm Board Of Directors


David Meeker, MD

Chairman
Dr. David Meeker, a member of Rhythm’s Board of Directors since 2015 and Chairman of the Board since 2017, was appointed President and Chief Executive…

Stuart Arbuckle

Mr. Arbuckle has served as a member of our Board of Directors since July 2019. Mr. Arbuckle is currently the Executive Vice President and Chief…

Todd Foley

Todd Foley is an experienced biotech investor and executive and serves on a number of MPM portfolio company boards, including Chiasma (NASDAQ: CHMA), CODA Biotherapeutics,…

Jennifer Good

Ms. Good has served as a member of our Board of Directors since June 2019. She is currently the President and Chief Executive Officer of…

Christophe R. Jean

Mr. Jean has served as a member of our Board of Directors since April 2015. He is a seasoned global pharmaceutical industry executive, having held…

Ed Mathers

Mr. Mathers has served as a member of our Board of Directors since March 2013. He joined NEA as a partner in August 2008 and…

David McGirr

Mr. McGirr has served as a member of our Board of Directors since November 2015. Mr. McGirr serves as a director of Insmed Inc., a…